Skip to content
Development-stage MedTech · AIRCHILL
Development-stage · no CE mark · no FDA clearance · not for patient use

Last reviewed 18 August 2026 · Trust Center / change history

Cooling belongs at the point of care.

AIRCHILL is a development-stage emergency-ventilation platform exploring controlled respiratory cooling as an integrated intervention for time-critical care. We are building the engineering, evidence, regulatory and reimbursement pathway in parallel.

Investor Snapshot → Explore AIRCHILL Review the evidence
AIRCHILL is a development-stage project and is not presented here as an approved medical device or as having established clinical efficacy.
0 min
30 min
1 h
5 h
6 h
The eventCollapse, arrest or injury
AIRCHILLThe window our next programme is designed to test and size
HeatstrokeGuideline target: cool within 30 minutes
TTM2 reached 34 °C≈ 5 h after the event · late systemic strategy, not the first-minute test
Newborn HIEMust start within 6 h. Standard of care

Minutes after the event; the axis is non-linear so the first hour stays readable. Both indications where cooling is standard of care sit at the fast end. Together with AIRCHILL’s porcine mechanism data and the broader animal timing/dose literature, that pattern supports a testable early-selective-cooling hypothesis. POLAR shows that timing alone is not enough, so AIRCHILL studies must prospectively test route, thermal distribution and phenotype together with timing.

What exists nowTRL ≈ 4 laboratory demonstrator, defined product concept and granted EU/US patents.
Next clinical validation goalGenerate the first AIRCHILL patient-performance and safety dataset, then prospectively test and size patient benefit.
Next capital milestoneBench, airway-safety and verification evidence that materially reduces product and regulatory uncertainty.
Investor pathSnapshot → evidence → regulatory plan → structured data room.
The device

One stack. Ventilation and controlled cooling.

A design concept from 2019 — a rendering, not a photograph of a finished device. What exists today is the laboratory demonstrator that carried the preclinical work.

In the first product
Transport ventilation with controlled respiratory cooling in one gas path.
Additional hardware modules
Monitoring, suction, ECG/defibrillation and telemedicine are intended primarily as purchased or OEM subsystems. Their development burden is integration, supplier control and system verification rather than re-developing mature hardware from scratch.
Build state
TRL ≈ 4 · no design freeze · no CE marking
Granted intellectual property

One patent family. Granted in Europe and the United States.

The AIRCHILL development programme is supported by a publicly reviewable patent family covering a transportable system for lowering body temperature via a cooled, oxygen-containing gas flow. Both granted rights are held solely by inventor Fabian Temme; the university is not a co-owner of the patents.

Europe · Granted

EP3509683B1

European Patent Office · granted 24 January 2024.
Transportable device and system for lowering body temperature over the airways using a cooled, oxygen-containing gas flow.

Open public patent record →

United States · Granted

US11395900B2

United States Patent · granted 26 July 2022.
Transportable device, system and method for providing a cooled, oxygen-containing gas flow.

Open public patent record →

Ownership

Clear founder ownership

Inventor Fabian Temme is the sole patent holder. There is no university co-ownership in the current patent ownership structure, creating a concentrated chain of title for the AIRCHILL development programme.

Product & IP details →

The product thesis

Bring controlled cooling closer to the moment it may matter.

Today, temperature-management workflows are often separated from the first minutes of emergency care. AIRCHILL explores whether respiratory cooling can be engineered into a transport-oriented ventilation platform — with the goal of making research into earlier, controlled intervention technically practical.

01 · Integration

Ventilation + cooling

One development concept instead of two disconnected workflows. The engineering question is whether controlled respiratory cooling can be integrated without compromising ventilation requirements.

02 · Workflow

Designed for time-critical care

The product architecture is considered from the ambulance and transport environment outward: compact workflows, controlled delivery and practical handling matter as much as thermal performance.

03 · Evidence

Turn the hypothesis into measured clinical evidence

Lead with the measured mechanism and preclinical safety, then use prospectively designed studies to test and size the human effect. That makes each development milestone explicit, measurable and investable.

Why this can become a company

A product is only one part of the investment case.

We are building the surrounding system that a serious MedTech program needs: technical development, an explicit evidence ladder, clinical-study planning, regulatory reasoning, reimbursement intelligence and procurement context.

E
Engineering platformA transport-oriented ventilation and controlled-cooling concept with clearly separated subsystems and development questions.
C
Clinical development logicResearch questions, study planning and evidence gaps are mapped instead of hidden behind promotional claims.
R
Regulatory & reimbursement workRegulatory strategy and payer/procurement pathways are treated as separate workstreams, not as assumptions of market access.
D
Data-rich diligenceSource registers, global EMS reimbursement research and scenario models provide a deeper diligence surface than a typical early-stage product site.
Evidence status

Each evidence gate is designed to turn a strong rationale into measurable clinical value.

AIRCHILL mechanism data, preclinical airway-safety work and external timing/dose animal evidence motivate a focused clinical-validation programme. Evidence boundaries remain explicit so each investment milestone has a measurable endpoint and the next study can test and size the effect.

Established literature

Therapeutic cooling research

The broader literature provides scientific context for temperature management. It does not automatically establish AIRCHILL efficacy. Explore research register →

AIRCHILL-specific evidence

Mechanism & development evidence

Existing project results support further investigation of the engineering and physiological mechanism. Product claims remain bounded by the available evidence. Evidence overview →

Next value inflection · clinical validation

Test and size the human effect

The next programme is designed to establish product-level safety and performance, then prospectively test and size indication-specific patient benefit. Study planner →

Development roadmap

Milestones investors can diligence.

Rather than presenting a single “launch date”, AIRCHILL is framed as a staged MedTech development program with technical, clinical, regulatory and market-access dependencies.

Current · in development1. Engineering maturity

Freeze the minimum certifiable configuration: the complete ventilation/cooling core, manufacturable system definition and verification strategy, with defined interfaces for purchased/OEM hardware modules rather than a throw-away MVP.

Next value-inflection gate2. Mechanism, safety & usability evidence

Close the most important technical and physiological evidence gaps before expanding clinical claims.

Planned · clinical validation3. Clinical feasibility & indication strategy

Use indication-specific research questions, endpoints and study designs rather than one broad efficacy narrative.

Planned · clinical validation4. Regulatory, reimbursement & procurement pathway

Align evidence generation with intended use, target markets and real purchasing/reimbursement pathways.

Due diligence

Go deeper than the pitch.

The strongest investor experience is not a glossy claim. It is a fast path from the thesis into the underlying evidence, assumptions and market-access work.

Due diligenceInvestor Data RoomStructured access to product, evidence, IP, regulatory, market, financial-planning and risk workstreams. ScienceEvidenceAn evidence-led view of AIRCHILL mechanism data, supporting preclinical context and the clinical programme designed to test and size patient benefit. Market accessRegulatory & ReimbursementPreliminary regulatory and reimbursement planning, clearly separated from established approvals. TransparencySources & AssumptionsSource directory, transferred sensitivities, derived values and data gaps behind the models.
Build the next evidence milestone

Looking for investors, clinical collaborators and engineering partners.

AIRCHILL is at a stage where disciplined development capital and the right partners can accelerate the next engineering and evidence milestones.

Start a conversation → Investor Data Room
AIRCHILLEvidenceRegulatory & reimbursementImpact models
AIRCHILL is a development-stage medical technology project. Information on this website is for research, planning and collaboration purposes and is not medical advice or a representation of regulatory approval or established clinical efficacy.